期刊文献+

安博诺与安博维治疗老年原发性高血压的临床疗效与安全性比较 被引量:2

Comparison of Clinical Efficacy and Safety:Ambolol and Ambroxol in the Treatment of Elderly Essential Hypertension
下载PDF
导出
摘要 目的通过比较安博诺与安博维治疗老年原发性高血压的临床疗效与安全性,探讨治疗老年原发性高血压的最佳用药方案。方法选择同期老年原发性高血压患者92例,在患者知情同意的情况下分为A组与B组,各46例,A组采用安博诺口服治疗,B组采用安博维口服治疗,比较两组患者就诊时、治疗2周后、治疗6周后与治疗12周后的血压变化情况与临床疗效,同时比较两组患者治疗期间出现的不良反应情况。结果两组患者就诊时收缩压与舒张压比较,差异无统计学意义;治疗2周后、治疗6周后与治疗12周后收缩压与舒张压比较,差异有统计学意义(P<0.05),A组优于B组;治疗12周后显效例数与临床有效例数比较,差异有统计学意义(P<0.05),A组优于B组;治疗过程中两组患者出现的不良反应轻微,不影响正常治疗。结论在药物治疗老年原发性高血压时,应首选安博诺治疗,可提高临床疗效,且安全可靠,临床应广泛采纳实行。 Objective To compare the clinical efficacy and safety of Ambro and Amberway in the treatment of elderly essential hypertension and discuss the best medication for the treatment of elderly patients with essential hypertension.Methods 92 elderly patients with primary hypertension were selected and divided into group A and group B in the same period,each group was 46 cases.The patients in group A were treated with Ambro oral treatment,the patients in group B were treated with Ambrovir oral treatment.Compared with that the changes of blood pressure and clinical curative effect at the time of treatment,after 2 weeks of treatment,after 6 weeks of treatment and after 12 weeks of treatment,the adverse reactions during treatment in the two groups.Results There was no significant difference in systolic blood pressure and diastolic blood pressure between the two groups at the time of treatment;the difference between systolic blood pressure and diastolic blood pressure was statistically significant after two weeks of treatment,six weeks of treatment,and twelve weeks of treatment(P<0.05),group A was better than group B;the differences about the number of clinically valid cases after 12 weeks of treatmen were statistically significant(P<0.05).Group A was better than group B;The adverse reactions were mild in two groups and did not affect the normal treatment.Conclusion In the treatment of elderly essential hypertension,Amporno should be the first choice,it can improve the clinical efficacy and it is safe and reliable.Amporno should be widely adopted.
作者 屠明君 杨东松 杜志祥 Tu Mingjun;Yang Dongsong;Du Zhixiang(Gulou District ModelWest Road Community Health Service Center,Department of General Practice,Nanjing,Jiangsu,210013,China)
出处 《当代医学》 2018年第21期104-106,共3页 Contemporary Medicine
关键词 安博诺 安博维 老年 原发性高血压 临床疗效 安全性 Ambonol Amberway Elderly Essential hypertension Clinical efficacy Safety
  • 相关文献

参考文献8

二级参考文献32

  • 1谢玉兰,任利群,邹继红,李洁.安博维与安博诺对老年高血压的短期疗效比较[J].现代医学,2006,34(6):417-419. 被引量:5
  • 2张维忠.新型固定剂量降压制剂ARB/HCTZ临床应用专家共识[J].中华高血压杂志,2007,15(z1):23-25. 被引量:10
  • 3徐道珍,刘晓梅,陈云国.安博诺治疗原发性高血压的临床观察[J].医学理论与实践,2006,19(6):664-665. 被引量:1
  • 4江凤林,杨侃,梁中书.厄贝沙坦/氢氯噻嗪复方片治疗轻中度原发性高血压的疗效观察[J].高血压杂志,2006,14(7):576-577. 被引量:25
  • 5Hagman M,Wilhelmsen L,Pennert K,et al.Factors of importance for prognosis in men with angina pectoris derived from a random population sample. The Muitifactor Primary Prevention Trial,Gothenburg,Sweden[J].Am J Cardiol, 1988,61 (8): 530-535.
  • 6Hansson L,Zanchetti A,Oarruthers SG,et al.Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group[J].Lancet,1998,351(9118):1755-1762.
  • 7Markham A,Ooa KL.Valsartan.A review of its pharmacology and therapeutic use in essential hypertension[J]. Drugs, 1997, 54(2):299-311.
  • 8Bramlage P,Durand-Zaleski I,Pesai N,The value of irbesartan in the management of hypertension[J].Expert Opin Pharrnacother, 2009, 10(11): 1817-31.
  • 9Bramiage P.Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension. Vasc Health Risk Manag[J].2009,5(1):213- 224.
  • 10Law MR,Wald NJ,Morris JK,et aI.Value of low dose combination treatment with blood pressure lowering drugs:analysis of 554 randomised trials[J]. BMJ, 2003,326(7404): 1427.

共引文献978

同被引文献5

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部